Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $14.5 million.

  • Northwest Biotherapeutics' Operating Expenses fell 420.9% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.8 million, marking a year-over-year increase of 169.74%. This contributed to the annual value of $67.9 million for FY2024, which is 1819.29% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Operating Expenses is $14.5 million, which was down 420.9% from $14.9 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Operating Expenses registered a high of $21.6 million during Q2 2022, and its lowest value of $10.4 million during Q3 2021.
  • For the 5-year period, Northwest Biotherapeutics' Operating Expenses averaged around $15.5 million, with its median value being $15.2 million (2024).
  • Over the last 5 years, Northwest Biotherapeutics' Operating Expenses had its largest YoY gain of 13573.72% in 2021, and its largest YoY loss of 7837.73% in 2021.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Operating Expenses stood at $10.7 million in 2021, then soared by 75.86% to $18.8 million in 2022, then fell by 16.98% to $15.6 million in 2023, then grew by 20.16% to $18.7 million in 2024, then fell by 22.48% to $14.5 million in 2025.
  • Its Operating Expenses stands at $14.5 million for Q3 2025, versus $14.9 million for Q2 2025 and $17.7 million for Q1 2025.